Svenska                Glossary                Search    
 
 
AboutTechnologyProjectInvestorMedia Releases 2012Contact
 
 
 
 
NeuroNova in Brief


We believe therapeutic neurogenesis and neuroprotection can revolutionize the treatment of several currently incurable neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and Huntington's disease.

 

   
© NeuroNova AB, Sweden, Tel: +46 (0)8 786 0900, Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it  
Sitemap Site policy 
 
 
Project Pipeline

Project

    Indication  

Pre-clin.

   IND  

 Phase I/II

 Phase II

 Phase III 

sNN0029ALS      
sNN0031Parkinson's disease     
More about our ProjectsImage

 Business Development

NeuroNova’s business strategy centers on developing novel therapeutic products based on neurogenesis in areas of high unmet medical need in neurodegenerative diseases.
More about business development.Image